Вы находитесь на странице: 1из 6

_JOSE __A.

ROSARIO MS, CCRA, CCRC_


LATIN REACH MONITORING
710 37TH STREET N.
ST. PETERSBURG, FLORIDA 33713
813-957-7037
jre368ec@westpost.net

_LICENSURE / CERTIFICATION _
2005 CCRA Certification
2004 Respiratory Therapy Licensure Maryland, #L0004198
2002 Hazardous Materials Training Certification
*
CCRC Certification
*
NBRC a"Pediatric/Neonatal Care certification
1989 Respiratory Therapy Licensure Florida, # RT0001988

_EDUCATION_

2006 Masters Degree in Clinical Research Administration


George Washington University
2002 Bachelors Degree in Clinical Research Administration
George Washington University
*
Air Critical Care (Care Flight) certification program
1994 Advanced Cardiac Life Support Adult and Pediatric program
*
DOT- Adult Air/Ground Transport certification program
*
A.A.S. Respiratory Care
University of NY, New York
_PROFESSIONAL WORK EXPERIENCE_
Aug 2009-Oct 2010 CORDIS, INC. (via Novella Clinical CRO)
Monitoring Cardiac Stenting with Dual-Anti-platelet therapy. Ongoing
Contract
CRA home based in Tampa, Florida.
May 2007-Nov 2009 BIOTRONIK, INC. (via Novella Clinical CRO)
18 month Contract CRA home based in Tampa, Florida.
Monitoring Device Registry study. Thirty-five sites nationwide
utilizing InForm EDC system.
Mar 2007- Jun 2007 ANORMED INC./GENZYME, INC. (via Chiltern CRO)
Contract CRA based in Tampa, Florida.
Assisting Sponsor Genzyme, Inc with transition of all studies and
sites from AnorMed, Inc. during buyout. Duties included Auditing/Data
Management at Vancouver, BC location.
Aug 2006- Jan 2007 GLAXOSMITHKLINE (via eReady Monitors CRO)
Six month Contract CRA based in Tampa, Florida
Duties include site training of ediaries used in Urology study and
maintaining the help desk phone for both English and Spanish-
speaking sites and subjects.
Oct 2005- Oct 2006 BRISTOL-MYERS SQUIBB (via Professional Access
CRO)
One year Contract CRA based in San Juan, Puerto Rico
Duties included Site screening and training, attending investigator
meetings, site initiation, on-site monitoring, clinical closeouts
and CRC training. Monthly travel to Miami was conducted towards the
end of the contract
Oct 2003- Oct 2005 NAVAL MEDICAL RESEARCH CENTER In-House CRA
Hematomimetics Program - _RESUS_ Study
Duties included protocol design, CRF design, Informed Consent
translation, site evaluation and training. FDA submitting of IND.
2003 Acme Research
Assistant CRA
Worked with this consortium as an assistant CRA co-monitoring
studies with senior CRAs.
2001-2003 Foundation Research, St. Petersburg, FL
Study Coordinator
1999-2001 Director Clinical Research, Largo, FL
Diagnostic Clinic
1998-2001 GCP Inc, Clearwater, FL
Independent Clinical Research Company
1994-1998 The Research Consortium, Inc., Seminole, FL
Study Coordinator/Site Manager

_RESEARCH EXPERIENCE (PARTIAL LIST)_

DEVICE STUDIES Evaluation of Stored EGMs and Event Recorders Using


The XXX Discovery Models 1174/1175/1273/1274/1275 Acute Evaluation of
Atrial Auto Capture Capability Using XXX DR Device
Evaluation of Acute and Chronic Lead Measurements using the XXX
Sweet Tip Rx
Evaluation of Benefits of Automated, Self-Programming Dual Sensor
DDDR Pacing and Automatic Mode Switching in XXX 400 DDDR Subjects.
A Prospective, Multi-Center Registry to Accurately Estimate the
All-Cause Complication Rates at 6-Months for Patients Undergoing
Generator Replacement Without a Planned System Modification.
Additionally, This Registry Will Prospectively Estimate the All-Cause
Complication Rates at 6-Months For Patients Undergoing Generator
Replacement With a Planned System Modification.
A Prospective, Randomized, Multi-Center, Double-Blind Trial to
Assess the Effectiveness and Safety of Different Durations of Dual
Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous
Coronary Intervention with the XXX Sirolimus-eluting Coronary Stent
PULMONARY STUDIES
A 12-week, Randomized, Double-Blind, Positive Control, Crossover
Study of XXX, XXX, and the Combination, as an Inhalation Solution in
Patients With Chronic Obstructive Pulmonary Disease
An Open-Label, Long-Term Study of the Safety and Tolerability of XXX
in Patients With Moderate to Severe COPD
A Four-Week, Double-Blind, Placebo-Controlled, Randomized,
Dose-Ranging, Parallel Group Study to Evaluate the Safety,
Tolerability and Efficacy of Oral XXX (20mg to 100mg BID ) Using
Pulmonary Hemodynamic Parameters and Clinical Response in
Out-Patients With Moderate to Severe COPD
Comparative Safety and Efficacy of XXX and XXX in the Treatment of
Acute Bacterial Exacerbation of Chronic Bronchitis
A Randomized, Double-Blind, Multicenter Comparison of the Efficacy
and Safety of XXX and XXX in the Treatment of Outpatients With
Community Acquired Pneumonia
A Randomized Multicenter Comparison of the Efficacy and Safety of
XXX and XXX in the Treatment of Patients With Acute Bacterial
Exacerbation of Chronic Bronchitis
Open Label Study to Evaluate the Efficacy and Tolerability of a Low-
Dose CCB/ACE Inhibitor Combination Agent- XXX 5/10 and 5/20 mg
A Double-Blind, Randomized, Placebo-Controlled Surveillance Study of
Asthma Event Outcomes in Subjects Receiving Either Usual
Pharmacotherapy of Asthma or Usual Pharmacotherapy Plus XXX 42MCG (2
Puffs) Twice Daily

_RESEARCH EXPERIENCE (CONTINUED)_

CARDIOLOGY STUDIES
A Phase II Randomized, Double Blind, Placebo-Controlled Study of The
Effect of XXX on Total Mortality and Adverse Cardiovascular Ischemic
Outcomes in Patients Undergoing CABG
A Phase III, Multicenter, International, Randomized, Double-Blind,
Aspirin-Controlled Trial to Evaluate the Efficacy and Safety of Two
Regimens with XXX, an Oral Platelet Glycoprotein IIb/IIIa Receptor
Antagonist, as Therapy For the Long Term Prevention of Secondary
Vascular Events in Patients After an Acute Coronary Syndrome.
Multinational, Multicenter, Double-Blind, Randomized, Active
Controlled, Parallel Group Study Comparing the Efficacy and Safety of
Long-Term Treatment With XXX, XXX, and Their Combination in High-Risk
Patients After Myocardial Infarction.
Randomized, Double Blind, Placebo Controlled, Multicenter Trial to
Evaluate the Efficacy and Safety of XXX as an Adjunct to Reperfusion
Therapy (Thrombolysis or Mechanical Reperfusion) in the Treatment of
Acute Anterolateral Myocardial Infarction.
Open Label Study to Evaluate the Efficacy and Tolerability of a Low-
Dose CCB/ACE Inhibitor Combination Agent- XXX 5/10 and 5/20 mg
Prospective Observational Study of XXX and Other Statins in
High-Risk Subjects.
A Study to Compare the Safety and Efficacy of XXX 30 mg BID Plus
Usual Asthma Care Versus Placebo Plus Usual Asthma Care in Relieving
Asthma Symptoms of Subjects With Asthma and Suspected Gastro
Esophageal Reflux (GER)
UROLOGY STUDIES
A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel
Group Study of the Efficacy and Safety of XXX 0.5mg in the Treatment
and Prevention of Progression of Benign Prostatic Hyperplasia
INFECTIOUS DESEASE STUDIES
A Double-Blind Trial Comparing 600mg XXX Every 12 Hours With 200mg
XXX Every 12 Hours For the Treatment of Vancomycin Resistant
Enterococcal Infections.
NEUROLOGY STUDIES
A Multicenter, Pharmacya"Based, Open-Label, Actual Use Study With
XXX to Assess Consumer Behavior, Compliance and Safety in a
Naturalistic Setting.
An Innovative Approach to the Treatment of Post-Herpetic Neuralgia:
An Open-Label Study of XXX

_RESEARCH EXPERIENCE (CONTINUED)_


GASTRO-INTESTINAL STUDIES
A 24 Week, Randomized, Open Label Study of Health Care Use and
Quality of Life With XXX 1mg Twice Daily Versus Traditional Therapy
in Females With Diarrhea-Predominant Irritable Bowel Syndrome
A Study to Compare the Safety and Efficacy of XXX 30 mg BID Plus
Usual Asthma Care Versus Placebo Plus Usual Asthma Care in Relieving
Asthma Symptoms of Subjects With Asthma and Suspected Gastro
Esophageal Reflux (GER)

DIABETES STUDIES
Rosiglitazone Evaluation: Advancing Current Treatment of Type 2
Diabetes
ORTHOPEADIC STUDIES
A Randomized Double-Blind, Multicenter Study Comparing the Safety
and Efficacy of Two Dosing Regimens of Oral XXX with Subcutaneous
Enoxaparin Sodium for the Prevention of Venous Thromboembolic Events
Following Elective Total Hip Replacement Surgery
RHEMATOID ARTHRITIS STUDIES
A Multicenter, Randomized, Blinded, Placebo Controlled Study to
Describe Long-term Safety of Daily Subcutaneous Injections of XXX in
Patients With Rheumatoid Arthritis
MIGRAINE/PAIN STUDIES
Patient Treatment Preference For and Satisfaction With Migraine
Headache Therapy: XXX Tablets Versus Current (non-triptan) Therapy
ONCOLOGY STUDIES
A Multi-Center, Open Label, Single-Arm Phase IV Trial Evaluating The
Diagnostic Utility of XXX Stimulated Thyroglobulin Testing For The
Surveillance of Patients With Treated Papillary or Follicular Thyroid
Carcinoma at Risk For Recurrence
OTHER STUDIES
A Sixteen-Week, Double-Blind and Observer-Blind-to-Lipid-Values,
Randomized, Parallel-Group, Multicenter, Active-Controlled Study to
Assess the Efficacy and Safety of XXX 80 mg Slow Release (SR)
Formulation Compared to XXX 10mg, XXX 40mg and XXX 40mg Administered
once Daily Every Evening at Bedtime in Patients with Primary
Hypercholesterolemia
_RESUS_: Restore Effective SUrvival in Shock - A Pivotal,
Randomized, Controlled, and Single-Blinded Trial of the Hemoglobin
Based Oxygen Carrier (HBOC), Bovine Polymerized Hemoglobin
(HBOC-201), For the Pre-hospital Resuscitation of Patients With
Severe Hemorrhagic Shock (HS)